Selective Peripheral Denervation (Bertrand Procedure) — CPB 0401 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0401 covering selective peripheral denervation (Bertrand procedure) for cervical dystonia, effective September 26, 2025. Billing teams handling CPT 64616 and 64640 need to verify medical necessity documentation before claims go out.

This policy change tightens the criteria your billing team must document to get selective peripheral denervation billing approved for Aetna members. CPB 0401 in Aetna's system governs when the Bertrand procedure clears medical necessity — and when it doesn't. The Aetna selective peripheral denervation coverage policy now draws a hard line between covered and experimental status based on two specific criteria. Miss either one, and you're looking at a claim denial.

Quick-Reference Table

Aetna Selective Peripheral Denervation Coverage Criteria and Medical Necessity Requirements 2025

Aetna covers selective peripheral denervation — also called the Bertrand procedure — for severe spasmodic torticollis (cervical dystonia) under two hard-stop criteria. Both must be met. There's no flexibility here.

Criterion one: The member's symptoms must be disabling. "Severe" alone isn't enough. The documentation must show functional disability — this means the patient's condition limits daily activity or work, not just that they experience muscle spasms. Your clinical notes need to reflect that explicitly.

Criterion two: The member must have failed prior therapy. Aetna accepts any of the following as evidence of failure:

That last point matters. If your patient developed resistance to Botox and you've got that documented, Aetna treats that as failed prior therapy — even without the full three-month injection trial. Build that into your intake documentation process now.

The coverage policy doesn't explicitly mention prior authorization for CPT 64616 or 64640, but that doesn't mean you skip the auth check. Aetna's surgical procedures at this level routinely require prior authorization depending on the member's plan. Verify auth requirements with the member's specific plan before scheduling.

The real issue here is documentation completeness, not clinical eligibility. Most patients who reach the Bertrand procedure genuinely meet these criteria. What sinks claims is thin records — no documented duration of prior therapy, no explicit language about disability, no resistance notation. Fix your intake forms to capture all of this before the procedure is performed.

Aetna Selective Peripheral Denervation Exclusions and Non-Covered Indications

Aetna classifies selective peripheral denervation as experimental, investigational, or unproven in two situations. First, when the member's symptoms are not disabling. Second, when the member has not failed medical management.

Aetna's stated rationale: the value of this procedure in non-disabled patients or those who haven't exhausted conservative treatment is unproven. This isn't just a coverage policy choice — Aetna is saying the clinical evidence doesn't support the procedure for those populations.

The practical implication for selective peripheral denervation billing: if you submit CPT 64640 for a patient who only received two months of botulinum toxin injections with no documented adverse reaction or resistance, Aetna denies it as experimental. That's not a soft denial you can appeal with a letter of medical necessity. You're arguing against an "experimental" designation, which is a much harder fight.

If you're treating a patient who fails to meet criteria but genuinely needs this procedure, loop in your compliance officer before billing. An ABN (Advance Beneficiary Notice equivalent for commercial payers) discussion with the patient may be appropriate.

Coverage Indications at a Glance

Aetna Selective Peripheral Denervation Billing Guidelines and Action Items 2025

The effective date for this modified policy is September 26, 2025. Claims for dates of service on or after that date will be adjudicated under these criteria. Here's what your billing team needs to do now.

1. Audit your documentation templates before September 26, 2025.
Your pre-procedure intake and clinical note templates must capture three things explicitly: (a) functional disability from cervical dystonia, (b) the type and duration of prior therapy tried, and (c) the reason therapy failed — side effects, resistance, or duration of three months. If your templates don't prompt for these, update them this week.

2. Build a prior therapy evidence trail into the chart.
Claims submitted under CPT 64616 (chemodenervation of neck muscles) and CPT 64640 (destruction by neurolytic agent, peripheral nerve) will be scrutinized for proof of failed conservative treatment. Pull prior claims for J0585, J0586, J0587, or J0588 and attach them to the record. If the patient had botulinum toxin treatment at another practice, get those records before you submit.

3. Confirm prior authorization requirements at the member plan level.
CPB 0401 governs Aetna's coverage policy position, but individual plan contracts determine prior auth requirements. Call or portal-check every Aetna member scheduled for this procedure. Do this at scheduling, not day-of.

4. Use ICD-10 code G24.3 — and make sure your documentation supports it.
G24.3 is spasmodic torticollis. Your claim must reflect the "severe, disabling" qualifier that drives medical necessity under CPB 0401. If the provider's diagnosis language says "cervical dystonia, moderate" and you're coding G24.3, that's a mismatch that will cost you on appeal.

5. Flag G80.1 if upper limb spasticity is a co-occurring condition.
G80.1 (spastic diplegic cerebral palsy) appears in the policy's ICD-10 codes. This likely reflects a secondary indication context. If your patient has a documented upper limb spasticity component, include G80.1 appropriately as a secondary diagnosis — but don't force it. Only code what's documented.

6. Train your coders on the "experimental" boundary.
The line between covered and experimental under this coverage policy is sharper than it looks on paper. Your coders and billing team should know: no documented disability = experimental. No failed prior therapy = experimental. Both must be present. Run a quick training before the effective date and flag this policy in your coding reference.

If you're uncertain how this applies to your patient mix — especially if you treat a high volume of movement disorder patients with complex prior treatment histories — talk to your compliance officer before September 26, 2025.

CPT, HCPCS, and ICD-10 Codes for Selective Peripheral Denervation Under CPB 0401

Covered CPT Codes (When Medical Necessity Criteria Are Met)

HCPCS Codes — Prior Therapy Documentation (Botulinum Toxin)

These codes are not billed for the Bertrand procedure itself. They represent the botulinum toxin therapy that must be documented as prior failed treatment. Claims history for these codes supports medical necessity for CPT 64616 and 64640.

Key ICD-10-CM Diagnosis Codes

One note on these ICD-10 codes: G24.3 is your primary workhorse here. Every claim for the Bertrand procedure under this coverage policy should include G24.3 when the diagnosis supports it. G80.1 is listed in the policy but reflects a secondary clinical context — don't default to it as a primary diagnosis unless it's directly documented.

The HCPCS codes for botulinum toxin (J0585 through J0588) are important for a reason many billing teams overlook. When you pull prior claims history to document failed botulinum toxin therapy, you're looking for these specific codes. If the patient's prior treatment was billed correctly, you have a clean claims trail. If the prior provider used miscellaneous or unlisted codes, you may need additional documentation to substantiate the treatment history for Aetna.